36725-37-8

Basic information

• Product Name: 6-(4-BROMOPHENYL)-4 5-DIHYDRO-2H-PYRIDA&
• Synonyms: 6-(4-BROMOPHENYL)-4 5-DIHYDRO-2H-PYRIDA&;6-(4-Bromophenyl)-4,5-dihydro-3(2H)-pyridazinone;3-(4-bromophenyl)-4,5-dihydro-1H-pyridazin-6-one
• CAS NO: 36725-37-8
• Molecular Formula: C₁₀H₉BrN₂O
• Molecular Weight: 253.1
• Product Categories: Building Blocks;Halogenated Heterocycles;Heterocyclic Building Blocks;Pyridazines;PyridazinesHeterocyclic Building Blocks;Building Blocks;Chemical Synthesis;Halogenated Heterocycles;Heterocyclic Building Blocks
• Mol File: 36725-37-8.mol
• Article Data: 11

Chemical Properties

• Melting Point: 167-171 °C(lit.)
• Appearance: /
• Density: 1.62 g/cm³
• Refractive Index: 1.667
• CAS DataBase Reference: 6-(4-BROMOPHENYL)-4 5-DIHYDRO-2H-PYRIDA&(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(4-BROMOPHENYL)-4 5-DIHYDRO-2H-PYRIDA&(36725-37-8)
• EPA Substance Registry System: 6-(4-BROMOPHENYL)-4 5-DIHYDRO-2H-PYRIDA&(36725-37-8)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 36725-37-8(Hazardous Substances Data)

Usage

General Description

6-(4-Bromophenyl)-4,5-dihydro-2H-pyridazin-3(2H)-one is a chemical compound with the molecular formula C11H10BrN3O. It is a heterocyclic aromatic compound that contains a pyridazine ring and a bromophenyl group. 6-(4-BROMOPHENYL)-4 5-DIHYDRO-2H-PYRIDA& is commonly used in organic synthesis as a building block for the preparation of various pharmaceuticals, agrochemicals, and other fine chemicals. Its structure and reactivity make it a valuable intermediate for the synthesis of diverse compounds with potential biological activity. Additionally, it is also used as an intermediate in the production of various dyes and pigments. Due to its versatile applications, 6-(4-Bromophenyl)-4,5-dihydro-2H-pyridazin-3(2H)-one is a widely studied and utilized compound in the field of organic chemistry.

InChI:InChI=1/C10H9BrN2O/c11-8-3-1-7(2-4-8)9-5-6-10(14)13-12-9/h1-4H,5-6H2,(H,13,14)

Upstream product

• 6340-79-0 4-oxo-4-(4-bromophenyl)butanoic acid 
• 108-86-1 bromobenzene 

Downstream Products

• 50636-57-2 6-(4-bromophenyl)-3(2H)-pyridazin-3-one 
• 66548-50-3 3-(p-bromophenyl)-6-chloropyridazine 
• 956150-95-1 3-phenyl-6-(4'-bromophenyl)-1,2,4-triazolo[4,3-b]pyridazine 
• 1268133-96-5 3-(4'-tolyl)-6-(4'-bromophenyl)-1,2,4-triazolo[4,3-b]pyridazine 
• 53346-62-6 3-(4-bromophenyl)-6-hydrazinopyridazine 
• 100953-64-8 6-(4-bromophenyl)-2-hydrazide-methyl-3(2H)-2,3-dihydropyridazin-3-one 
• 67820-85-3 N'-[6-(4-cyano-phenyl)-5-methyl-pyridazin-3-yl]-hydrazinecarboxylic acid tert-butyl ester 
• 67820-76-2 N'-[6-(4-bromo-phenyl)-pyridazin-3-yl]-hydrazinecarboxylic acid ethyl ester 
• 67820-95-5 N'-(6-phenyl-pyridazin-3-yl)-hydrazinecarboxylic acid ethyl ester 
• 67821-02-7 4-[4-methyl-6-(N-methyl-hydrazino)-pyridazin-3-yl]-benzonitrile 
• 67820-75-1 N'-[6-(4-cyano-phenyl)-pyridazin-3-yl]-hydrazinecarboxylic acid ethyl ester 
• 66548-54-7 3-chloro-6-(4-cyano-phenyl)-pyridazine 
• 52240-10-5 4-(1,6-dihydro-6-oxo-3-pyridazinyl)benzonitrile 
• 101871-42-5 3-(4-bromo-phenyl)-1,4,5,6-tetrahydro-pyridazine 

Relevant articles and documents

Synthesis, anti-convulsant activity and molecular docking study of novel thiazole pyridazinone hybrid analogues

Pyridazinone analogues have been known to be potential candidates for anticonvulsant agents. We have identified several pyridazinone-based anticonvulsant agents. As a continuation to our previous research, a series of hybrid pyridazinone-thiazole connected through amide linkage were designed and synthesized. Among these, compound SP-5F demonstrated significant anticonvulsant activity with median effective dose of 24.38 mg/kg (MES) and 88.23 mg/kg (scPTz). Results of GABA estimation showed a marked increase in the GABA level when compared with control. Molecular docking studies at the active site of GABA receptor, further confirmed the GABA modulatory effects of SP-5F.

Design, Synthesis, and Pharmacological Screening of Pyridazinone Hybrids as Anticonvulsant Agents

A series of new hybrid benzimidazole containing pyridazinones derivatives were designed and synthesized in accordance with the pharmacophoric requirements essential for the anticonvulsant activity. The synthesized compounds were evaluated for anticonvulsant activity on mice by the gold standard maximal electroshock (MES) and subcutaneous pentylenetetrazole (scPTZ)-induced seizure models. Among the compounds tested, SS-4F showed significant anticonvulsant activity in both the screens with ED50 values of 25.10 and 85.33 mg/kg in the MES and scPTZ screens, respectively. Compound SS-4F emerged as safer and effective anticonvulsant due to its several-fold higher protective indices. Further, the gamma-aminobutyric acid (GABA) estimation result showed a marked increase in the GABA level (1.7-fold) as compared to the control, which was further confirmed by good binding properties with the GABAA receptor.

Synthesis and in-vitro antifungal activity of 6-substituted-phenyl-2- {[(4′-substituted phenyl-5′-thioxo)-1,2,4-triazol-3-yl]-methyl}-2,3, 4,5-tetrahydropyridazin-3-one derivatives

The synthetic pathway for 6-substituted phenyl-2-[{(4′-substituted phenyl-5′-thioxo)-1,2,4-triazol-3-yl}-methyl]-2,3,4,5-tetrahydropyridazin- 3-one compounds was achieved by a sequence of reactions starting from respective aryl hydrocarbons and is illustrated in Scheme1. All the compounds were tested for their in vitro antifungal activity on five fungal species, namely Candida albicans, Trichophyton rubrum, Aspergillus flavus, Aspergillus niger and Penicillium citrinium. The chloro substituent derivative (compound 5g) showed the highest activity against all the fungal species. The MIC of the standard drug voriconazole was between 0.10 - 0.40 μg/mL against all the fungal species except A. fumigatus. The two electronegative groups of Cl were increasing the activity of 1,2,4-triazole. As we increased the bulky group or aromatic group on benzene ring, there was a decrease of activity as in case of compound l.